Logo

StimLabs Receives the US FDA’s 510(k) Clearance for Corplex P as a Management Therapy for Acute and Chronic Wounds

Share this
StimLabs

StimLabs Receives the US FDA’s 510(k) Clearance for Corplex P as a Management Therapy for Acute and Chronic Wounds

Shots:

  • The company received the US FDA’s 510(k) clearance for its human umbilical cord-derived Corplex P. The company had earlier launched an intact placental membrane allograft in 2016
  • The clearance was granted based on the results from the clinical study depicting the safety and effectiveness of Corplex P through testing, compliance with pre-market submission requirements
  • Corplex P is a medical device derived from the human umbilical cord extracellular matrix (ECM) approved and indicated for the management of acute and chronic wounds

Ref: StimLabs | Image: StimLabs

Related News:- SeaStar Medical Receives Canadian Patent Claiming Coverage of its Selective Cytopheretic Device Technology

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions